Recruiting PHASE2 INTERVENTIONAL 1-arm NCT06225843

Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis (EGIA-003)

A Proof-of-Concept Phase II Trial to Evaluate the EMT Inhibitor Sotevtamab Combined With FOLFOX Administered as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis

Sponsor: Alethia Biotherapeutics

Conditions Metastatic Colorectal Cancer

Interventions FOLFOX Sotevtamab

Updated 6 times since 2024 Last updated: Feb 18, 2025 Started: Feb 15, 2024 Primary completion: Mar 31, 2026 Completion: Jun 30, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Metastatic Colorectal Cancer and is currently actively recruiting participants. Alethia Biotherapeutics leads this study, which shows 6 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Recruiting PHASE2
Mar 2025 — Sep 2025 [monthly]

Recruiting PHASE2
Sep 2024 — Mar 2025 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Apr 2024 — Jul 2024 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Feb 2024 — Apr 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alethia Biotherapeutics

Data source: Alethia Biotherapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Montreal, Canada